CME Presentations

Hereditary Angioedema (HAE)



  • Luann Curry

    Luann Curry

    Luann Curry

    Interview Participant - Patient with HAE

  • Marc Riedl,  MD, MS

    Marc Riedl, MD, MS

    Marc Riedl, MD, MS

    Professor of Medicine

    Marc Riedl, MD, MS is a professor of medicine and clinical director of the United States Hereditary Angioedema Association (US HAEA) Angioedema Center at the University of California, San Diego (UCSD), where he also serves as clinical service chief for allergy and immunology. He directs an active clinical research program focused on angioedema and immunodeficiency conditions and lectures frequently at national and international medical conferences. He has published more than 140 peer-reviewed manuscripts and serves on numerous scientific committees, as well as appointed expert panels for the US Food and Drug Administration (FDA) and National Institutes of Health (NIH). He serves on the US HAEA Medical Advisory Board, the Immune Deficiency Foundation Physician Advisory Committee, and the Board of Directors for the Western Society of Allergy, Asthma, and Immunology.
  • Timothy Craig, DO, FAAAAI, FACAAI, FACP, FACOI

    Timothy Craig, DO, FAAAAI, FACAAI, FACP, FACOI

    Timothy Craig, DO, FAAAAI, FACAAI, FACP, FACOI

    Tenured Professor of Medicine

    Timothy Craig, DO, FAAAAI, FACAAI, FACP, FACOI is a tenured professor of medicine, pediatrics, and biomedical sciences and is a distinguished educator at Pennsylvania State University (PSU). He is director of the Allergy, Immunology, and Respiratory Clinical Research, as well as the PSU Alpha-1 Foundation Clinical Resource Center and the International Angioedema Resource Center (ACARE). He has served as a leader in multiple organizations, including the Asthma Diagnosis and Treatment Interest Section Chair for the American Academy of Allergy, Asthma & Immunology (AAAAI). He also serves on the Medical Advisory Board for the US Hereditary Angioedema Association. A successful clinical researcher and mentor, Dr. Craig has published more than 350 manuscripts, delivered more than 500 invited lectures and 450 abstracts, and has served on numerous editorial boards.

CME Information

Global LogoPQH Logo

Shifting Treatment Paradigms to Combat Hereditary Angioedema (HAE) Attacks

This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the National Organization for Rare Disorders, Inc. (NORD).


This activity is supported by educational grants from Ionis Pharmaceuticals, Inc. and Pharming Healthcare, Inc.


This activity was released on September 28, 2023 and is valid for 12 months. Requests for credit must be made no later than September 28, 2024.


The educational design of this activity addresses the needs of allergy/immunology specialists, primary care physicians, pediatricians, nurse practitioners, physician assistants, and other clinicians involved in the care of patients with HAE.


The frequency and severity of hereditary angioedema (HAE) attacks have serious repercussions for patients. With the emergence of new clinical data on the long-term efficacy of prophylaxis in minimizing these attacks, as well as more convenient options for medication administration, education can help clinicians stay up to date with therapeutic strategies and guidelines to improve patient outcomes.

Join an expert panel of allergy and immunology specialists to discuss evidence-based approaches to earlier diagnoses of HAE, the role of long-term prophylaxis and clinical data on existing and emerging options, and patient-physician collaboration in formulating treatment plans. The panel will also review guideline-compliant treatment plans that incorporate patient preferences. Participating clinicians will be more knowledgeable about both prophylactic and on-demand therapies and will be able to engage in shared decision-making to provide care that mirrors their patients’ needs.


After completing this activity, the participant should be better able to:
  • Describe the clinical manifestations and diagnostic criteria for HAE
  • Evaluate clinical evidence for approved and emerging agents to reduce HAE attacks
  • Discuss strategies to enhance patient-clinician collaboration to improve patients’ quality of life


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.


Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 1 hour to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:


Name of Faculty or Presenter Reported Financial Relationship
Timothy Craig, DO Tenured Professor of Medicine Pediatrics and Biomedical Sciences Penn State Health Consulting Fee (e.g., Advisory Board): CSL-Behring, Astria, Intellia, BioMarin, Biocryst, Ionis, Takeda Contracted Research (Principal Investigators must provide information, even if received by the institution): CSL-Behring, Astria, Intellia, BioMarin, Ionis, Takeda, GSK, Pfizer, Pharvaris, Kalvista Honoraria: CSL-Behring, Astria, Intellia, BioMarin, Biocryst, Ionis, Takeda, Kalvista Speaker's Bureau: CSL-Behring, Takeda, Grifols
Marc Riedl, MD, MS Professor of Medicine Clinical Director – US HAEA Angioedema Center University of California, San Diego Consulting Fee (e.g., Advisory Board): Astria, Biocryst, Biomarin, CSL Behring, Cycle Pharma, Grifols, Kalvista, Ono Pharma, Pfizer, Pharming, Pharvaris, Sanofi-Regeneron, Takeda Contracted Research (Principal Investigators must provide information, even if received by the institution): Biocryst, Biomarin, CSL Behring, Ionis, Kalvista, Pharvaris, Takeda Honoraria: CSL Behring, Grifols, Pharming, Takeda
Luann Curry Interview Participant - Patient with HAE Nothing to disclose


The planners and managers at Global Education Group have no relevant financial relationships to disclose.

The planners and managers at PlatformQ Health Education have no relevant financial relationships to disclose.  


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Physician Accreditation Support:

For information about the physician accreditation of this program, please contact Global at 303-395-1782 or

Technical Support:

For any technical issues or issues with your CME Certificate, please contact, ImmunologyLive, at 877-394-1306 or at